Literature DB >> 23074243

Central nervous system neuropeptide Y signaling via the Y1 receptor partially dissociates feeding behavior from lipoprotein metabolism in lean rats.

Jennifer M Rojas1, John M Stafford, Sanaz Saadat, Richard L Printz, Annette G Beck-Sickinger, Kevin D Niswender.   

Abstract

Elevated plasma triglyceride (TG) levels contribute to an atherogenic dyslipidemia that is associated with obesity, diabetes, and metabolic syndrome. Numerous models of obesity are characterized by increased central nervous system (CNS) neuropeptide Y (NPY) tone that contributes to excess food intake and obesity. Previously, we demonstrated that intracerebroventricular (icv) administration of NPY in lean fasted rats also elevates hepatic production of very low-density lipoprotein (VLDL)-TG. Thus, we hypothesize that elevated CNS NPY action contributes to not only the pathogenesis of obesity but also dyslipidemia. Here, we sought to determine whether the effects of NPY on feeding and/or obesity are dissociable from effects on hepatic VLDL-TG secretion. Pair-fed, icv NPY-treated, chow-fed Long-Evans rats develop hypertriglyceridemia in the absence of increased food intake and body fat accumulation compared with vehicle-treated controls. We then modulated CNS NPY signaling by icv injection of selective NPY receptor agonists and found that Y1, Y2, Y4, and Y5 receptor agonists all induced hyperphagia in lean, ad libitum chow-fed Long-Evans rats, with the Y2 receptor agonist having the most pronounced effect. Next, we found that at equipotent doses for food intake NPY Y1 receptor agonist had the most robust effect on VLDL-TG secretion, a Y2 receptor agonist had a modest effect, and no effect was observed for Y4 and Y5 receptor agonists. These findings, using selective agonists, suggest the possibility that the effect of CNS NPY signaling on hepatic VLDL-TG secretion may be relatively dissociable from effects on feeding behavior via the Y1 receptor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23074243      PMCID: PMC3532466          DOI: 10.1152/ajpendo.00351.2012

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  71 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins.

Authors:  Tony K T Lam; Roger Gutierrez-Juarez; Alessandro Pocai; Sanjay Bhanot; Patrick Tso; Gary J Schwartz; Luciano Rossetti
Journal:  Nat Med       Date:  2007-02-04       Impact factor: 53.440

3.  Neuropeptide Y and corticotropin-releasing hormone concentrations within specific hypothalamic regions of lean but not ob/ob mice respond to food-deprivation and refeeding.

Authors:  M Jang; D R Romsos
Journal:  J Nutr       Date:  1998-12       Impact factor: 4.798

4.  Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice.

Authors:  Emil D Bartels; Morten Lauritsen; Lars B Nielsen
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

5.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

6.  Neuropeptide Y suppresses anorexigenic output from the ventromedial nucleus of the hypothalamus.

Authors:  Melissa J S Chee; Martin G Myers; Christopher J Price; William F Colmers
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

Review 7.  Distribution of NPY receptors in the hypothalamus.

Authors:  Sergueï O Fetissov; Jutta Kopp; Tomas Hökfelt
Journal:  Neuropeptides       Date:  2004-08       Impact factor: 3.286

8.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

9.  Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet.

Authors:  Kelly A Posey; Deborah J Clegg; Richard L Printz; Jaeman Byun; Gregory J Morton; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Denis G Baskin; Jay W Heinecke; Stephen C Woods; Michael W Schwartz; Kevin D Niswender
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-12-30       Impact factor: 4.310

10.  Weight-reducing effects of the plasma protein encoded by the obese gene.

Authors:  J L Halaas; K S Gajiwala; M Maffei; S L Cohen; B T Chait; D Rabinowitz; R L Lallone; S K Burley; J M Friedman
Journal:  Science       Date:  1995-07-28       Impact factor: 47.728

View more
  7 in total

1.  Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation.

Authors:  Jennifer M Rojas; Eveline Bruinstroop; Richard L Printz; Aldijana Alijagic-Boers; Ewout Foppen; Maxine K Turney; Leena George; Annette G Beck-Sickinger; Andries Kalsbeek; Kevin D Niswender
Journal:  Mol Metab       Date:  2015-01-16       Impact factor: 7.422

Review 2.  Neuropeptide Y in Alcohol Addiction and Affective Disorders.

Authors:  Annika Thorsell; Aleksander A Mathé
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-31       Impact factor: 5.555

Review 3.  Prophylactic and therapeutic vaccines for obesity.

Authors:  Ha-Na Na; Hun Kim; Jae-Hwan Nam
Journal:  Clin Exp Vaccine Res       Date:  2013-12-18

4.  Brain Control of Plasma Cholesterol Involves Polysialic Acid Molecules in the Hypothalamus.

Authors:  Xavier Brenachot; Thomas Gautier; Emmanuelle Nédélec; Valérie Deckert; Amélie Laderrière; Danaé Nuzzaci; Caroline Rigault; Aleth Lemoine; Luc Pénicaud; Laurent Lagrost; Alexandre Benani
Journal:  Front Neurosci       Date:  2017-05-03       Impact factor: 4.677

5.  Higher Serum Neuropeptide Y Levels Are Associated with Metabolically Unhealthy Obesity in Obese Chinese Adults: A Cross-Sectional Study.

Authors:  Hao-Neng Tang; Fen Xiao; Ya-Ru Chen; Si-Qi Zhuang; Yue Guo; Hui-Xuan Wu; Hou-De Zhou
Journal:  Mediators Inflamm       Date:  2020-08-04       Impact factor: 4.711

Review 6.  Metabolic-associated fatty liver disease and lipoprotein metabolism.

Authors:  Joerg Heeren; Ludger Scheja
Journal:  Mol Metab       Date:  2021-04-20       Impact factor: 7.422

7.  Rictor/mTORC2 facilitates central regulation of energy and glucose homeostasis.

Authors:  Heidi E Kocalis; Scott L Hagan; Leena George; Maxine K Turney; Michael A Siuta; Gloria N Laryea; Lindsey C Morris; Louis J Muglia; Richard L Printz; Gregg D Stanwood; Kevin D Niswender
Journal:  Mol Metab       Date:  2014-02-19       Impact factor: 7.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.